Casa Grande

Researchers are evaluating the effectiveness of combining tarlatamab with durvalumab, carboplatin, and etoposide compared to the combination of durvalumab, carboplatin, and etoposide alone in treating patients with untreated extensive stage small-cell lung cancer ES-SCLC. The main goal is to see if the addition of tarlatamab can help patients live longer overall. This is a phase 3, open-label, randomized study conducted across multiple centers. Participants are assigned to one of two groups. One group receives tarlatamab combined with durvalumab, carboplatin, and etoposide for four treatment cycles, followed by maintenance treatment with tarlatamab and durvalumab. The other group receives durvalumab, carboplatin, and etoposide for four cycles, followed by durvalumab alone. All drugs are given as intravenous infusions. The study lasts up to approximately 3.5 to 4 years to assess survival and disease progression. During the study, participants will undergo regular assessments including evaluations of overall survival and progression-free survival. Other measures include response to treatment, disease control, duration of response, and monitoring for treatment-related adverse events. Blood tests will evaluate drug levels and antibody development. The research team will carefully monitor participants throughout the treatment and follow-up periods, keeping track of their health and any side effects.

Researchers are evaluating the effectiveness of trastuzumab deruxtecan T-DXd in patients with HER2-positive IHC 3 locally advanced, unresectable, or metastatic solid tumors in the United States. This observational study focuses on patients who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options. The study excludes patients with breast, colorectal, non-small cell lung cancer, gastricgastroesophageal junction cancers, and hematological malignancies. Participants will be enrolled at approximately 30 sites including community oncology practices, hospital systems, and academic medical centers. They will start treatment with T-DXd as part of routine clinical care according to the FDA label. The study is designed to reflect real-world clinical practice and will observe patients from the point they begin T-DXd treatment. During the study, researchers will collect data on tumor response and treatment outcomes over up to 2.5 years after enrollment. They will assess real world response rate, duration of response, time to treatment discontinuation, and time to next treatment. Participants clinical progress and outcomes will be monitored through their usual healthcare visits, with no additional interventional procedures required for the study duration.